Mesuximide References

Mesuximide
Clinical data
Trade names	Celontin
AHFS/ Drugs.com	Consumer Drug Information
MedlinePlus	a682028
Routes of; administration	By mouth ( capsules)
ATC code	N03AD03 ( WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Metabolism	Hepatic ( demethylation and glucuronidation)
Metabolites	N-desmethylmethosuximide
Elimination half-life	1.4–2.6 hours (mesuximide); 28–38 hours (active metabolite)
Excretion	Urine
Identifiers
	IUPAC name (RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione;
CAS Number	77-41-8 ;
PubChem CID	6476;
IUPHAR/BPS	7228;
DrugBank	DB05246 ;
ChemSpider	6231 ;
UNII	0G76K8X6C0;
KEGG	D00404 ;
ChEMBL	ChEMBL697 ;
CompTox Dashboard ( EPA)	DTXSID5023293 ;
ECHA InfoCard	100.000.934
Chemical and physical data
Formula	C12H13NO2
Molar mass	203.241 g·mol−1
3D model ( JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES O=C2N(C(=O)CC2(c1ccccc1)C)C;
	InChI InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3 ; Key:AJXPJJZHWIXJCJ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)^[1] and Celontin (United States).^[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.^[3]

Medical use

is indicated for the control of absence seizures that are refractory to other drugs.^[2]

References

^ Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Archived from the original on April 22, 2005. Retrieved August 21, 2006.
^ ^a ^b Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.
^ Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ (November 1979). "Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy". Neurology. 29 (11): 1509–13. doi: 10.1212/wnl.29.11.1509. PMID 116142. S2CID 43643797.

This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.

[Petinutin-1] Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Archived from the original on April 22, 2005. Retrieved August 21, 2006.

[Celontin-2] Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.

[pmid116142-3] Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ (November 1979). "Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy". Neurology. 29 (11): 1509–13. doi: 10.1212/wnl.29.11.1509. PMID 116142. S2CID 43643797.

[1]

[2]

[3]

Clinical data

Trade names	Celontin
AHFS/ Drugs.com	Consumer Drug Information
MedlinePlus	a682028
Routes of administration	By mouth ( capsules)
ATC code	N03AD03 ( WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Metabolism	Hepatic ( demethylation and glucuronidation)
Metabolites	N-desmethylmethosuximide
Elimination half-life	1.4–2.6 hours (mesuximide) 28–38 hours (active metabolite)
Excretion	Urine
Identifiers
IUPAC name (RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione
CAS Number	77-41-8^Y
PubChem CID	6476
IUPHAR/BPS	7228
DrugBank	DB05246^N
ChemSpider	6231^Y
UNII	0G76K8X6C0
KEGG	D00404^Y
ChEMBL	ChEMBL697^Y
CompTox Dashboard ( EPA)	DTXSID5023293
ECHA InfoCard	100.000.934
Chemical and physical data
Formula	C₁₂H₁₃NO₂
Molar mass	203.241 g·mol⁻¹
3D model ( JSmol)	Interactive image
Chirality	Racemic mixture
SMILES O=C2N(C(=O)CC2(c1ccccc1)C)C
InChI InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3^Y Key:AJXPJJZHWIXJCJ-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)